Medical - Devices
Compare Stocks
5 / 10Stock Comparison
LFWD vs GMED vs SYK vs MDT vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
LFWD vs GMED vs SYK vs MDT vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $10M | $11.51B | $112.69B | $99.94B | $161.07B |
| Revenue (TTM) | $22M | $3.10B | $25.12B | $35.48B | $10.58B |
| Net Income (TTM) | $-20M | $587M | $3.25B | $4.61B | $2.98B |
| Gross Margin | 38.3% | 50.9% | 63.5% | 61.9% | 66.3% |
| Operating Margin | -76.7% | 17.2% | 22.4% | 17.9% | 30.5% |
| Forward P/E | — | 16.7x | 19.1x | 13.8x | 43.3x |
| Total Debt | $2M | $119M | $14.86B | $28.52B | $303M |
| Cash & Equiv. | $2M | $526M | $4.01B | $2.22B | $3.37B |
LFWD vs GMED vs SYK vs MDT vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lifeward Ltd. (LFWD) | 100 | 6.1 | -93.9% |
| Globus Medical, Inc. (GMED) | 100 | 142.6 | +42.6% |
| Stryker Corporation (SYK) | 100 | 145.8 | +45.8% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LFWD vs GMED vs SYK vs MDT vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LFWD lags the leaders in this set but could rank higher in a more targeted comparison.
GMED ranks third and is worth considering specifically for growth exposure and valuation efficiency.
- Rev growth 16.7%, EPS growth 422.7%, 3Y rev CAGR 42.2%
- PEG 0.54 vs MDT's 35.17
- +19.0% vs LFWD's -58.3%
Among these 5 stocks, SYK doesn't own a clear edge in any measured category.
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Lower P/E (13.8x vs 43.3x)
- Beta 0.47 vs GMED's 1.29
ISRG is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 5.5% 10Y total return vs GMED's 264.4%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- 20.5% revenue growth vs LFWD's -14.1%
- 28.2% margin vs LFWD's -90.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs LFWD's -14.1% | |
| Value | Lower P/E (13.8x vs 43.3x) | |
| Quality / Margins | 28.2% margin vs LFWD's -90.4% | |
| Stability / Safety | Beta 0.47 vs GMED's 1.29 | |
| Dividends | 3.6% yield, 36-year raise streak, vs SYK's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +19.0% vs LFWD's -58.3% | |
| Efficiency (ROA) | 175.8% ROA vs LFWD's -78.4%, ROIC 6.0% vs -122.9% |
LFWD vs GMED vs SYK vs MDT vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
LFWD vs GMED vs SYK vs MDT vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
MDT leads 2 • LFWD leads 0 • GMED leads 0 • SYK leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 1610.4x LFWD's $22M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to LFWD's -90.4%. On growth, GMED holds the edge at +27.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $22M | $3.1B | $25.1B | $35.5B | $10.6B |
| EBITDAEarnings before interest/tax | -$17M | $745M | $6.3B | $9.4B | $3.8B |
| Net IncomeAfter-tax profit | -$20M | $587M | $3.2B | $4.6B | $3.0B |
| Free Cash FlowCash after capex | -$17M | $605M | $4.3B | $5.4B | $2.8B |
| Gross MarginGross profit ÷ Revenue | +38.3% | +50.9% | +63.5% | +61.9% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -76.7% | +17.2% | +22.4% | +17.9% | +30.5% |
| Net MarginNet income ÷ Revenue | -90.4% | +18.9% | +12.9% | +13.0% | +28.2% |
| FCF MarginFCF ÷ Revenue | -76.4% | +19.5% | +17.1% | +15.2% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -32.7% | +27.0% | +11.4% | +8.8% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +82.7% | +66.7% | +56.0% | -11.9% | +18.8% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), GMED offers better value at 0.70x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $10M | $11.5B | $112.7B | $99.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $10M | $11.1B | $123.5B | $126.2B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.39x | 21.70x | 35.03x | 21.60x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.70x | 19.06x | 13.80x | 43.35x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.70x | 2.36x | 35.17x | 2.65x |
| EV / EBITDAEnterprise value multiple | — | 18.51x | 20.31x | 14.32x | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 0.47x | 3.92x | 4.49x | 2.98x | 16.00x |
| Price / BookPrice ÷ Book value/share | 9.33x | 2.55x | 5.02x | 2.08x | 9.17x |
| Price / FCFMarket cap ÷ FCF | — | 19.54x | 26.31x | 19.28x | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-146 for LFWD. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), GMED scores 9/9 vs LFWD's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -145.5% | +13.0% | +15.0% | +9.4% | +16.9% |
| ROA (TTM)Return on assets | -78.4% | +11.3% | +6.9% | +175.8% | +14.8% |
| ROICReturn on invested capital | -122.9% | +8.9% | +11.4% | +6.0% | +15.0% |
| ROCEReturn on capital employed | -108.5% | +10.4% | +13.0% | +7.5% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 9 | 6 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.19x | 0.03x | 0.66x | 0.59x | 0.02x |
| Net DebtTotal debt minus cash | -$585,000 | -$408M | $10.8B | $26.3B | -$3.1B |
| Cash & Equiv.Liquid assets | $2M | $526M | $4.0B | $2.2B | $3.4B |
| Total DebtShort + long-term debt | $2M | $119M | $14.9B | $28.5B | $303M |
| Interest CoverageEBIT ÷ Interest expense | -41.85x | 81.13x | 6.72x | 9.08x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $476 for LFWD. Over the past 12 months, GMED leads with a +19.0% total return vs LFWD's -58.3%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs LFWD's -49.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.6% | -2.5% | -15.2% | -18.1% | -19.3% |
| 1-Year ReturnPast 12 months | -58.3% | +19.0% | -22.5% | -2.8% | -15.4% |
| 3-Year ReturnCumulative with dividends | -87.0% | +46.3% | +5.5% | -4.2% | +49.6% |
| 5-Year ReturnCumulative with dividends | -95.2% | +16.1% | +21.5% | -27.7% | +58.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | +264.4% | +187.1% | +26.5% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -49.3% | +13.5% | +1.8% | -1.4% | +14.4% |
Risk & Volatility
Evenly matched — GMED and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than GMED's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GMED currently trades 83.9% from its 52-week high vs LFWD's 38.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.23x | 0.52x | 0.42x | 1.00x |
| 52-Week HighHighest price in past year | $17.76 | $101.40 | $404.87 | $106.33 | $603.88 |
| 52-Week LowLowest price in past year | $0.67 | $51.79 | $289.91 | $77.16 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +38.1% | +83.9% | +72.7% | +73.3% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 49.8 | 45.0 | 24.3 | 27.3 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 11K | 998K | 2.1M | 7.8M | 1.8M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LFWD as "Buy", GMED as "Buy", SYK as "Buy", MDT as "Buy", ISRG as "Buy". Consensus price targets imply 59.0% upside for LFWD (target: $11) vs 29.6% for GMED (target: $110). For income investors, MDT offers the higher dividend yield at 3.57% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $10.75 | $110.29 | $389.62 | $109.50 | $622.60 |
| # AnalystsCovering analysts | 5 | 36 | 50 | 49 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | +3.6% | — |
| Dividend StreakConsecutive years of raises | — | — | 34 | 36 | — |
| Dividend / ShareAnnual DPS | — | — | $3.36 | $2.78 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.6% | 0.0% | +3.2% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
LFWD vs GMED vs SYK vs MDT vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LFWD or GMED or SYK or MDT or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -14. 1% for Lifeward Ltd. (LFWD). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Lifeward Ltd. (LFWD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LFWD or GMED or SYK or MDT or ISRG?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Globus Medical, Inc. wins at 0. 54x versus Medtronic plc's 35. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — LFWD or GMED or SYK or MDT or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -95. 2% for Lifeward Ltd. (LFWD). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus LFWD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LFWD or GMED or SYK or MDT or ISRG?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus Globus Medical, Inc. 's 1. 23β — meaning GMED is approximately 190% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — LFWD or GMED or SYK or MDT or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -14. 1% for Lifeward Ltd. (LFWD). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, LFWD leads at 58. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LFWD or GMED or SYK or MDT or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -90. 4% for Lifeward Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -76. 7% for LFWD. At the gross margin level — before operating expenses — GMED leads at 67. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LFWD or GMED or SYK or MDT or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Globus Medical, Inc. (GMED) is the more undervalued stock at a PEG of 0. 54x versus Medtronic plc's 35. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 29. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LFWD: 59. 0% to $10. 75.
08Which pays a better dividend — LFWD or GMED or SYK or MDT or ISRG?
In this comparison, MDT (3.
6% yield), SYK (1. 1% yield) pay a dividend. LFWD, GMED, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is LFWD or GMED or SYK or MDT or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 1. 1% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, LFWD: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LFWD and GMED and SYK and MDT and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LFWD is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ISRG is a mid-cap high-growth stock. SYK, MDT pay a dividend while LFWD, GMED, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.